Infection News

Strategies seeking to increase COVID-19 vaccine and booster uptake in Black patients with rheumatic diseases should consider and offer responses for racial, ethnic and socioeconomic factors, according to researchers.

Long COVID symptoms are more common in patients with inflammatory rheumatic disease vs. those without such conditions, according to data published in The Lancet Rheumatology.

Patients with autoimmune diseases or long COVID who used a personalized digital care program alongside other non-pharmacologic strategies were more likely to achieve better health-related quality of life scores, according to data.

This episode delves into the history of the hygiene hypothesis. What do we know about different exposures changing risk for asthma and allergies, and do these exposures have the same protection for autoimmunity?

Researchers created a symptom-based scoring system that may help diagnose long COVID more easily. The scoring system is based on 12 common symptoms identified in a study that included almost 10,000 participants.

The FDA on Thursday granted full approval for Paxlovid, making it the first oral antiviral pill approved by the FDA to treat COVID-19 in adults.

The current understanding of long COVID’s pathogenesis may be better served by looking to other diseases and syndromes, particularly fibromyalgia, according to a speaker at the 2023 Biologic Therapies Summit.

Additional COVID-19 vaccine doses can occasionally “bully” a humoral response in patients who are immunocompromised, according to a presenter at the 2023 Biologic Therapies Summit.

All immunocompromised adults should receive the high-dose formulation of the influenza vaccine, according to a presenter at the Biologic Therapies Summit.

Communication between rheumatologists and patients with immune-mediated conditions will be essential for navigating COVID-19 in the endemic phase, according to a presenter at the Biologic Therapies Summit.